M&A Deal Summary

Kriya Therapeutics Acquires Tramontane

On September 6, 2023, Kriya Therapeutics acquired life science company Tramontane

Acquisition Highlights
  • This is Kriya Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Kriya Therapeutics’ 1st transaction in Spain.

M&A Deal Summary

Date 2023-09-06
Target Tramontane
Sector Life Science
Buyer(s) Kriya Therapeutics
Deal Type Add-on Acquisition

Target

Tramontane

Barcelona, Spain
Tramontane is a gene therapy company focused on developing treatments for prevalent neurodegenerative and metabolic diseases. Tramontane uses adeno-associated viral vectors to express therapeutic proteins of relevance in the management of multiple diseases, including Non-alcoholic steatohepatitis (NASH), Type 2 diabetes, Obesity, Alzheimer’s disease, Parkinson disease, and other central disorders associated with impaired cognition and behavior.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Kriya Therapeutics

Redwood City, California, United States

Category Company
Sector Life Science
DESCRIPTION

Kriya Therapeutics is a fully integrated company provides novel technologies and therapeutics in gene therapy. Kriya is organized into four principal business units: Kriya Technologies™, Kriya Therapeutics™, Kriya R&D™, and Kriya Manufacturing™. Kriya Therapeutics is based in Redwood City, California.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Spain M&A 1 of 1
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-07 Warden Bio

United States

Warden Bio is a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Warden Bio is based in United States.

Buy -